{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:28:03Z","timestamp":1786336083429,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13607-w","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:35:45Z","timestamp":1780536945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical effectiveness of three months once-weekly Isoniazid and Rifapentine regimen for treatment of Latent TB Infection: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Malaisamy","family":"Muniyandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskara Chary","family":"Kothoju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthick","family":"Chelvanayagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balagopal","family":"Balachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharathidasan","family":"Palani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateshprabhu","family":"Janagaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaykaravell","family":"Thirupathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karikalan","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"11","key":"13607_CR1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","volume":"16","author":"H Alsdurf","year":"2016","unstructured":"Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269\u201378.","journal-title":"Lancet Infect Dis"},{"key":"13607_CR2","unstructured":"World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: WHO. 2018. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241550239. Accessed on 20th June 2025."},{"issue":"3","key":"13607_CR3","doi-asserted-by":"publisher","first-page":"1900655","DOI":"10.1183\/13993003.00655-2019","volume":"54","author":"A Cohen","year":"2019","unstructured":"Cohen A, Mathiasen VD, Sch\u00f6n T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655.","journal-title":"Eur Respir J"},{"issue":"10","key":"13607_CR4","doi-asserted-by":"publisher","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","volume":"13","author":"RMGJ Houben","year":"2016","unstructured":"Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152.","journal-title":"PLoS Med"},{"issue":"6","key":"13607_CR5","doi-asserted-by":"crossref","first-page":"e0287313","DOI":"10.1371\/journal.pone.0286740","volume":"18","author":"A Chauhan","year":"2023","unstructured":"Chauhan A, George N, Sharma A, Gupta S, Chatterjee P, Vashist RP, et al. The prevalence of tuberculosis infection in India: a systematic review and meta-analysis. PLoS ONE. 2023;18(6):e0287313.","journal-title":"PLoS ONE"},{"issue":"3\/4","key":"13607_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.14745\/ccdr.v43i34a01","volume":"43","author":"S Kiazyk","year":"2017","unstructured":"Kiazyk S, Ball TB. Latent tuberculosis infection: An overview. Can Commun Dis Rep. 2017;43(3\/4):62\u20136.","journal-title":"Can Commun Dis Rep"},{"key":"13607_CR7","unstructured":"World Health Organization. Global tuberculosis report 2024. Geneva, World Health Organization. 2024. Available from: https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024. Accessed on 18th May 2025."},{"issue":"12","key":"13607_CR8","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.socscimed.2009.03.041","volume":"68","author":"K L\u00f6nnroth","year":"2009","unstructured":"L\u00f6nnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med. 2009;68(12):2240\u20136.","journal-title":"Soc Sci Med"},{"key":"13607_CR9","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Geneva: WHO. 2020. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240001503. Accessed on 07th July 2025."},{"issue":"5","key":"13607_CR10","doi-asserted-by":"publisher","first-page":"e0155525","DOI":"10.1371\/journal.pone.0155525","volume":"11","author":"Y Tadesse","year":"2016","unstructured":"Tadesse Y, Gebre N, Daba S, Gashu Z, Habte D, Hiruy N, et al. Uptake of isoniazid preventive therapy among under-five children: TB contact investigation as an entry point. PLoS ONE. 2016;11(5):e0155525.","journal-title":"PLoS ONE"},{"key":"13607_CR11","unstructured":"World Health Organization. Recommended TPT regimens. TB Knowledge Sharing Platform. Available from: https:\/\/tbksp.who.int\/en\/node\/1271. Accessed on 26th July 2025."},{"key":"13607_CR12","doi-asserted-by":"publisher","first-page":"2502010","DOI":"10.1080\/22221751.2025.2502010","volume":"14","author":"QL Ruan","year":"2025","unstructured":"Ruan QL, Li T, Zhang Q, Zhao J, Wang L, Guo H, Chen H, Liu W. Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB). Emerg Microbes Infect. 2025;14:2502010.","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"13607_CR13","first-page":"1","volume":"18","author":"I Ilavarasan","year":"2024","unstructured":"Ilavarasan I, Ariharanathan V, Devi CS. Efficacy of short-course weekly isoniazid and rifapentine regimen as tuberculosis preventive treatment among population at risk of developing disease: a systematic review and meta-analysis. J Clin Diagn Res. 2024;18(1):1\u20139.","journal-title":"J Clin Diagn Res"},{"issue":"8","key":"13607_CR14","first-page":"e00317","volume":"65","author":"KK Radtke","year":"2021","unstructured":"Radtke KK, Dodd LE, Williams PJ, Deshpande D, Keung CF, Berman J, Peloquin CA, Dooley KE, Weiner M, Savic RM. Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection: a translational pharmacokinetic-pharmacodynamic modeling study. Antimicrob Agents Chemother. 2021;65(8):e00317\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"13607_CR15","first-page":"100234","volume":"31","author":"A Bhargava","year":"2024","unstructured":"Bhargava A. The 3HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India. Lancet Reg Health Southeast Asia. 2024;31:100234.","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"25","key":"13607_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.15585\/mmwr.mm6725a5","volume":"67","author":"AS Borisov","year":"2018","unstructured":"Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, et al. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2018;67(25):723\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"13607_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M17-0609","volume":"167","author":"D Zenner","year":"2017","unstructured":"Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167(4):248\u201355.","journal-title":"Ann Intern Med"},{"key":"13607_CR18","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"13607_CR19","doi-asserted-by":"crossref","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355.","DOI":"10.1136\/bmj.i4919"},{"key":"13607_CR20","unstructured":"Sch\u00fcnemann H, Broz J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and."},{"issue":"1","key":"13607_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1005136","volume":"365","author":"NA Martinson","year":"2011","unstructured":"Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11\u201320.","journal-title":"N Engl J Med"},{"issue":"23","key":"13607_CR22","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies RI, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155\u201366.","journal-title":"N Engl J Med"},{"key":"13607_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.tube.2018.05.013","volume":"111","author":"HY Sun","year":"2018","unstructured":"Sun HY, Huang YC, Huang YS, Su WJ, Huang WC, Chien YJ, Chen YM, Chen SY, Chen MY. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: a multicentre randomised controlled trial in Taiwan. Tuberculosis. 2018;111:121\u20136.","journal-title":"Tuberculosis"},{"issue":"5","key":"13607_CR24","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1513\/AnnalsATS.201704-326OC","volume":"15","author":"RN Moro","year":"2018","unstructured":"Moro RN, Scott NA, Vernon A, Goldberg SV, Schwartzman K, Reves R, Belknap R, Villarino ME, Sterling TR. Exposure to latent tuberculosis treatment during pregnancy. The PREVENT TB and the iAdhere trials. Ann Am Thorac Soc. 2018;15(5):570\u201380.","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"13607_CR25","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/imj.13601","volume":"47","author":"JT Denholm","year":"2017","unstructured":"Denholm JT, McBryde ES, Eisen D, Street A, Matchett E, Chen C, Shultz T, Biggs B, Leder K. SIRCLE: a randomised controlled cost comparison of self-administered short\u2010course isoniazid and rifapentine for cost\u2010effective latent tuberculosis eradication. Intern Med J. 2017;47(12):1433\u20136.","journal-title":"Intern Med J"},{"issue":"4","key":"13607_CR26","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1353\/hpu.2015.0126","volume":"26","author":"G Lines","year":"2015","unstructured":"Lines G, Hunter P, Bleything S. Improving treatment completion rates for latent tuberculosis infection: a review of two treatment regimens at a community health center. J Health Care Poor Underserved. 2015;26(4):1428\u201339.","journal-title":"J Health Care Poor Underserved"},{"issue":"9","key":"13607_CR27","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.5588\/ijtld.14.0829","volume":"19","author":"EE Bliven-Sizemore","year":"2015","unstructured":"Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Swindells S, Mac Kenzie WR, Menzies RI, LoBue P, Villarino ME. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis. 2015;19(9):1039\u201344.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"13607_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/cid\/civ766","volume":"62","author":"NL Stennis","year":"2016","unstructured":"Stennis NL, Burzynski JN, Herbert C, Nilsen D, Macaraig M. Treatment for tuberculosis infection with 3 months of isoniazid and rifapentine in New York City Health Department clinics. Clin Infect Dis. 2016;62(1):53\u20139.","journal-title":"Clin Infect Dis"},{"issue":"36","key":"13607_CR29","doi-asserted-by":"publisher","first-page":"e4126","DOI":"10.1097\/MD.0000000000004126","volume":"95","author":"YW Huang","year":"2016","unstructured":"Huang YW, Yang SF, Yeh YP, Tsao TCY, Tsao SM. Impacts of 12-dose regimen for latent tuberculosis infection: treatment completion rate and cost-effectiveness in Taiwan. Med (Baltim). 2016;95(36):e4126.","journal-title":"Med (Baltim)"},{"issue":"1","key":"13607_CR30","doi-asserted-by":"publisher","first-page":"ofw038","DOI":"10.1093\/ofid\/ofv220","volume":"3","author":"M Juarez-Reyes","year":"2016","unstructured":"Juarez-Reyes M, Gallivan M, Chyorny A, O\u2019Keeffe L, Shah NS. Completion rate and side-effect profile of three-month isoniazid and rifapentine treatment for latent tuberculosis infection in an urban county jail. Open Forum Infect Dis. 2016;3(1):ofw038.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"13607_CR31","doi-asserted-by":"crossref","first-page":"ofw039","DOI":"10.1093\/ofid\/ofw039","volume":"3","author":"A Yamin","year":"2016","unstructured":"Yamin A, Bornstein E, Hensel R, Mohamed O, Kempker RR. Predictors of latent tuberculosis infection treatment after introduction of a new regimen: a retrospective cohort study at an inner city clinic. Open Forum Infect Dis. 2016;3(1):ofw039.","journal-title":"Open Forum Infect Dis"},{"key":"13607_CR32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12879-017-2245-8","volume":"17","author":"AH McClintock","year":"2017","unstructured":"McClintock AH, Eastment MC, McKinney CM, Narita M, Dhanireddy S, O\u2019Hare AM, Ohl ME, Schwartzman K. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine. BMC Infect Dis. 2017;17:146.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"13607_CR33","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.5588\/ijtld.18.0035","volume":"22","author":"MM Macaraig","year":"2018","unstructured":"Macaraig MM, Jalees M, Lam C, Burzynski J. Improved treatment completion with shorter treatment regimens for latent tuberculous infection. Int J Tuberc Lung Dis. 2018;22(11):1344\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1suppl","key":"13607_CR34","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1177\/0033354919826557","volume":"134","author":"C Wheeler","year":"2019","unstructured":"Wheeler C, Mohle-Boetani J. Completion rates, adverse effects, and costs of a 3-month and 9-month treatment regimen for latent tuberculosis infection in California inmates, 2011\u20132014. Public Health Rep. 2019;134(1suppl):S71\u20139.","journal-title":"Public Health Rep"},{"key":"13607_CR35","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ijid.2020.05.009","volume":"96","author":"JY Feng","year":"2020","unstructured":"Feng JY, Lin HH, Lin HC, Su WJ, Hsu YH, Wang JY, Hsieh MJ, Su IJ. Safety and treatment completion of latent tuberculosis infection treatment in the elderly population-A prospective observational study in Taiwan. Int J Infect Dis. 2020;96:550\u20137.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"13607_CR36","first-page":"e02042","volume":"65","author":"SY Lin","year":"2021","unstructured":"Lin SY, Lin WR, Chang CW, Lee JJ, Chen YH, Lin HH, Yu MC. Completion and adverse drug events of latent tuberculosis infection treatment in patients receiving dialysis: predictors and impacts of different regimens in a prospective cohort study. Antimicrob Agents Chemother. 2021;65(4):e02042\u201320.","journal-title":"Antimicrob Agents Chemother"},{"key":"13607_CR37","doi-asserted-by":"crossref","unstructured":"An Y, Khun KE. Factors associated with incomplete tuberculosis preventive treatment: a retrospective analysis of six-years programmatic data in Cambodia. Sci Rep. 2024;14.","DOI":"10.1038\/s41598-024-67845-6"},{"issue":"6","key":"13607_CR38","doi-asserted-by":"publisher","first-page":"e1252","DOI":"10.1093\/cid\/ciab209","volume":"73","author":"HL Huang","year":"2021","unstructured":"Huang HL, Huang WC, Lin KD, Liu SS, Lee MR, Cheng MH, Chin CS, Lu PL, Sheu CC, Wang JY, Lee IT. Completion rate and safety of programmatic screening and treatment for latent tuberculosis infection in elderly patients with poorly controlled diabetic mellitus: a prospective multicenter study. Clin Infect Dis. 2021;73(6):e1252\u201360.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"13607_CR39","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.jmii.2021.09.013","volume":"55","author":"TF Chiu","year":"2022","unstructured":"Chiu TF, Yen MY, Shie YH, Huang HL, Chen CC, Yen YF. Determinants of latent tuberculosis infection and treatment interruption in long-term care facilities: A retrospective cohort study in Taiwan. J Microbiol Immunol Infect. 2022;55(6):1310\u20137.","journal-title":"J Microbiol Immunol Infect"},{"issue":"5","key":"13607_CR40","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/IPC.0000000000000518","volume":"25","author":"TL Sweeney","year":"2017","unstructured":"Sweeney TL, Ahern JW, Alston WK. Completion Rate and Safety of 12-Dose Isoniazid and Rifapentine for Latent Tuberculosis in a Predominantly Refugee Cohort. Infect Dis Clin Pract. 2017;25(5):272\u20134.","journal-title":"Infect Dis Clin Pract"},{"issue":"1","key":"13607_CR41","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s12879-025-10832-7","volume":"25","author":"S Pangprasertkul","year":"2025","unstructured":"Pangprasertkul S, Buawangpong N, Pinyopornpanish K, Jiraporncharoen W, Angkurawaranon C. Treatment completion and safety profile of once-weekly 3HP regimen for tuberculosis preventive treatment in children and adolescents: a systematic review. BMC Infect Dis. 2025;25(1):436.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"13607_CR42","doi-asserted-by":"publisher","first-page":"e20172838","DOI":"10.1542\/peds.2017-2838","volume":"141","author":"AT Cruz","year":"2018","unstructured":"Cruz AT, Starke JR. Completion rate and safety of tuberculosis infection treatment with shorter regimens. Pediatrics. 2018;141(2):e20172838.","journal-title":"Pediatrics"},{"issue":"8","key":"13607_CR43","doi-asserted-by":"publisher","first-page":"741","DOI":"10.5588\/ijtld.21.0676","volume":"26","author":"M Jaswal","year":"2022","unstructured":"Jaswal M, Farooq S, Madhani F, Noorani S, Salahuddin N, Amanullah F, Khowaja S, Safdar N, Khan A, Yuen C, Keshavjee S, Becerra M, Hussain H, Malik AA. Implementing 3HP vs. IPT as TB preventive treatment in Pakistan. Int J Tuberc Lung Dis. 2022;26(8):741\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"key":"13607_CR44","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12879-016-1549-4","volume":"16","author":"AL Stuurman","year":"2016","unstructured":"Stuurman AL, Vonk Noordegraaf-Schouten M, van Kessel F, Oordt-Speets AM, Sandgren A, van der Werf MJ. Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review. BMC Infect Dis. 2016;16:257.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"13607_CR45","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.5588\/ijtld.18.0168","volume":"22","author":"Y Hamada","year":"2018","unstructured":"Hamada Y, Ford N, Schenkel K, Getahun H. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review. Int J Tuberc Lung Dis. 2018;22(12):1422\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"22","key":"13607_CR46","first-page":"586","volume":"67","author":"D Menzies","year":"2018","unstructured":"Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, Villarino ME, Bliven-Sizemore EE, Gao L, Sun Q, Bonnet M, Jablonski K, Dodd LE, Sterling TR. Uptake and completion of tuberculosis preventive treatment using 12-dose, weekly isoniazid-rifapentine (3HP) regimen in program settings. MMWR Morb Mortal Wkly Rep. 2018;67(22):586\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"13607_CR47","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/cid\/civ323","volume":"61","author":"TR Sterling","year":"2015","unstructured":"Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, Weis S, Ho C, Villarino ME, Tuberculosis Trials Consortium, Sterling TR. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study. Clin Infect Dis. 2015;61(4):527\u201335.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"13607_CR48","first-page":"e1304","volume":"73","author":"SY Tseng","year":"2021","unstructured":"Tseng SY, Chen HY, Hsueh PR, Huang YF, Kuo YL, Chen CP. Patterns of symptom occurrence and systemic drug reactions (SDRs) with 3HP (iAdhere study). Clin Infect Dis. 2021;73(6):e1304\u201312.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13607-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13607-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13607-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T03:35:51Z","timestamp":1786332951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13607-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13607"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13607-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1452"}}